SN-38 NMP–Vitamin E TPGS Formulation for Solubility and Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
SN-38, the active metabolite of irinotecan, is poorly soluble in pharmaceutically acceptable solvents and has low affinity to lipid membranes, limiting its use as an anticancer drug due to poor solubility and oral absorption.
Innovation Solution
A pharmaceutical composition comprising SN-38 with a mixture of excipients such as N-Methylpyrrolidone (NMP) and Vitamin E TPGS, optionally with polymers like Hydroxypropyl cellulose (HPC) or 50/50 poly(lactic-co-glycolic acid) (PLGA), formulated as a liquid or gel to enhance solubility and oral absorption without precipitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SN-38 is used as an anticancer drug, then high cytotoxicity is achieved, but poor solubility in pharmaceutically acceptable solvents limits its use
Solution Approach 1:
The patent uses N-Methylpyrrolidone (NMP) as an intermediary solvent to dissolve SN-38, which is otherwise insoluble in water and most pharmaceutically acceptable solvents. NMP acts as a bridge that allows the highly cytotoxic but insoluble SN-38 to be delivered in a bioavailable form. The patent also employs Vitamin E TPGS and polymers as mediators to enhance solubility and stability.
Solution Approach 2:
The patent changes the physical and chemical parameters of the formulation system by using non-aqueous solvents (NMP) and adjusting the composition ratios of excipients (Vitamin E TPGS, polymers, surfactants). This parameter change enables SN-38 to achieve sufficient solubility while maintaining its high cytotoxicity, resolving the contradiction between reliability and quantity of substance.
2Reliability
If SN-38 is administered, then high anti-tumor efficacy is achieved, but low affinity to lipid membranes reduces oral absorption
Solution Approach 1:
The patent creates a composite formulation system combining SN-38 with NMP, Vitamin E TPGS, polymers (such as PLGA, HPC, HPMC), and surfactants. This composite material approach enhances the lipophilic characteristics and membrane affinity of the formulation, enabling SN-38 to be effectively absorbed orally while maintaining its high anti-tumor efficacy.
Solution Approach 2:
The patent uses lipid-soluble excipients and surfactants as intermediaries to facilitate the interaction between SN-38 and lipid membranes. These mediators enhance the permeability and absorption of SN-38 through the gastrointestinal tract, overcoming the low natural affinity of SN-38 to lipid membranes while preserving its therapeutic effectiveness.
3Ease of operation
If SN-38 is formulated for oral administration, then patient compliance is improved, but solubility in pharmaceutically acceptable solvents remains poor
Solution Approach 1:
The patent extracts SN-38 from its conventional parenteral formulation context and develops a completely new oral formulation system. By removing the dependency on intravenous administration and creating a self-contained oral dosage form using NMP-based excipients, the patent improves patient compliance while addressing the solubility challenge through the specialized excipient composition.
4Quantity of substance
If CPT-11 is used instead of SN-38, then aqueous solubility is improved, but cytotoxicity is reduced
Solution Approach 1:
The patent segments the functions of solubility enhancement and cytotoxicity delivery by using a two-component system: NMP-based excipients provide solubility, while SN-38 provides cytotoxicity. This segmentation allows each component to optimize its function without compromising the other, unlike CPT-11 where the solubility enhancement comes at the cost of reduced cytotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves higher solubility of SN-38, allowing for effective oral administration with reduced systemic side effects and improved patient compliance, providing sustained-release profiles and enhanced tumor tissue concentrations for treating cancers like colorectal, liver, and pancreatic cancer.
Implementation Method 1
N-Methylpyrrolidone (NMP)...the SN-38 is dissolved in the mixture of the excipients
Implementation Method 2
Vitamin E TPGS (VitE TPGS)...enhance solubility and oral absorption
Implementation Method 3
the SN-38 is dissolved in the mixture of the excipients without precipitation
Data Source
AI summary
Formulations with enhanced SN-38 solubility and oral absorption. In one embodiment, a formulation or a pharmaceutical composition comprises (a) 7-Ethyl-10-hydroxy-camptothecin (SN-38); and (b) a mixture of pharmaceutically acceptable excipients comprising (i) N-Methylpyrrolidone; and (ii) Vitamin E TPGS or a copolymer, the copolymer being 50/50 poly(lactic-co-glycolic acid), or 75/25 poly(lactic-co-glycolic acid) (PLGA); with the provision that if the VitE TPGS is present, the mixture of the excipients further comprises a polymer selected from the group consisting of Hydroxypropyl cellulose, Hydroxypropyl methylcellulose, VP/VAc copolymer 60/40, poloxamer 407, and Lauroyl Macrogol-32 glycerides; wherein the pharmaceutical composition contains no water, is in a liquid or a gel form, and the SN-38 is dissolved in the mixture of the excipients without precipitation.